EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Ravulizumab During the Acute Phase of Neuromyelitis Optica Spectrum Disorder

Koji Tsuzaki iD, Goro Mitsui iD, Yasunobu Inagaki, Naoko Uehara, Shinichi Wada, Toshiaki Hamano iD

Case Reports in Neurological Medicine · 2026-01 · 2026 (1)

DOI: 10.1155/crnm/1518364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Neurological Medicine, online erschienen am 06.04.2026. Verfasst von Koji Tsuzaki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kansai Electric Power Hospital, 2-1-7 Fukushima Fukushima-ku, Osaka, 553-0003, Japan, kanden-hsp.jp. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ravulizumab is effective in preventing relapse of neuromyelitis optica spectrum disorder (NMOSD). However, its efficacy during the acute phase of NMOSD has rarely been reported. Case We report the case of a 66‐year‐old woman with anti‐aquaporin‐4 antibody‐positive NMOSD. Six years ago, the patient had impaired vision and visual field loss in her right eye and received steroid therapy at another hospital for 6 months, after which no further treatment was given. On admission, she presented with weakness in both lower limbs, numbness from the chest to the lower body, and impaired bladder sensation. Neurological examination revealed bilateral lower limb weakness and hypoesthesia below the 4th thoracic spinal segment. The Expanded Disability Status Scale (EDSS) score was 3.5. Cerebrospinal fluid examination revealed mild cytosis, elevated protein levels, an elevated immunoglobulin G index, and positive oligoclonal bands. Magnetic resonance imaging revealed longitudinally extensive transverse myelitis from the 2nd to 8th thoracic vertebral levels. She was diagnosed with a relapse of NMOSD. After one course of steroid pulse therapy, she developed complete paraplegia in both legs. The EDSS score was 8.5. Immunoadsorption therapy, prednisolone, and azathioprine were initiated; however, these treatments were ineffective. Ravulizumab was administered immediately after immunoadsorption therapies. Treatment with prednisolone, azathioprine, and ravulizumab was continued. Her symptoms gradually improved, and prednisolone was gradually tapered and discontinued. She could walk independently after 6 months. The EDSS score was 3.5 at the time of discharge.

Conclusion

Ravulizumab may be a viable treatment option when administered during the acute phase of NMOSD.

Autor:innen und Institutionen

  • Department of Neurology, Kansai Electric Power Hospital, 2-1-7 Fukushima Fukushima-ku, Osaka, 553-0003, Japan, kanden-hsp.jp.
  • Division of Clinical Neurology, Kansai Electric Power Medical Research Institute, 2-1-7 Fukushima Fukushima-ku, Osaka, 553-0003, Japan, kepmri.org.
  • Division of Sleep Medicine, Kansai Electric Power Medical Research Institute, 2-1-7 Fukushima Fukushima-ku, Osaka, 553-0003, Japan, kepmri.org.

ORCID-Profile: Koji Tsuzaki, Goro Mitsui, Toshiaki Hamano

Zitieren

APA

Tsuzaki, K., Mitsui, G., Inagaki, Y., Uehara, N., Wada, S., & Hamano, T. (2026). Efficacy of Ravulizumab During the Acute Phase of Neuromyelitis Optica Spectrum Disorder. Case Reports in Neurological Medicine, 2026(1). https://doi.org/10.1155/crnm/1518364

Vancouver

Tsuzaki K, Mitsui G, Inagaki Y, Uehara N, Wada S, Hamano T. Efficacy of Ravulizumab During the Acute Phase of Neuromyelitis Optica Spectrum Disorder. Case Reports in Neurological Medicine. 2026;2026(1). doi:10.1155/crnm/1518364

BibTeX
@article{Tsuzaki2026,
  author = {Tsuzaki, Koji and Mitsui, Goro and Inagaki, Yasunobu and Uehara, Naoko and Wada, Shinichi and Hamano, Toshiaki},
  title = {Efficacy of Ravulizumab During the Acute Phase of Neuromyelitis Optica Spectrum Disorder},
  journal = {Case Reports in Neurological Medicine},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crnm/1518364}
}
Kostenlos starten →